VIR

Company Overview — What Does Vir Biotechnology, Inc. Do?

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Vir Biotechnology, Inc. (VIR) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO George A. Scangos and employs approximately 580 people. With a market capitalization of $1.4B, VIR is one of the notable companies in the Healthcare sector.

Vir Biotechnology, Inc. (VIR) Stock Rating — Reduce (April 2026)

As of April 2026, Vir Biotechnology, Inc. receives a Reduce rating with a composite score of 39.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.VIR ranks #2,384 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Vir Biotechnology, Inc. ranks #293 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

VIR Stock Price and 52-Week Range

Vir Biotechnology, Inc. (VIR) currently trades at $9.49. The stock lost $0.34 (3.5%) in the most recent trading session. The 52-week high for VIR is $10.94, which means the stock is currently trading -13.3% from its annual peak. The 52-week low is $4.16, putting the stock 128.4% above its annual trough. Recent trading volume was 1.4M shares, reflecting moderate market activity.

Is VIR Overvalued or Undervalued? — Valuation Analysis

Vir Biotechnology, Inc. (VIR) carries a value factor score of 16/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.91x, versus the sector average of 2.75x. The price-to-sales ratio is 213.44x, compared to 1.66x for the average Healthcare stock.

At current multiples, Vir Biotechnology, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Vir Biotechnology, Inc. Profitability — ROE, Margins, and Quality Score

Vir Biotechnology, Inc. (VIR) earns a quality factor score of 37/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -79.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -60.7% versus the sector average of -33.1%.

On a margin basis, Vir Biotechnology, Inc. reports gross margins of 99.0%, compared to 71.5% for the sector. The operating margin is -24085.8% (sector: -66.1%). Net profit margin stands at -22521.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -92.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

VIR Debt, Balance Sheet, and Financial Health

Vir Biotechnology, Inc. has a debt-to-equity ratio of 31.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.54x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $170M.

VIR has a beta of 1.51, meaning it is more volatile than the broader market — a $10,000 investment in VIR would be expected to move 51.5% more than the S&P 500 on any given day. The stability factor score for Vir Biotechnology, Inc. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Vir Biotechnology, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Vir Biotechnology, Inc. reported revenue of $7M and earnings per share (EPS) of $-3.16. Net income for the quarter was $-609M. Gross margin was 99.0%. Operating income came in at $-663M.

In FY 2025, Vir Biotechnology, Inc. reported revenue of $69M and earnings per share (EPS) of $-3.16. Net income for the quarter was $-438M. Gross margin was 100.0%. Revenue grew -7.6% year-over-year compared to FY 2024. Operating income came in at $-479M.

In Q3 2025, Vir Biotechnology, Inc. reported revenue of $240,000 and earnings per share (EPS) of $-1.17. Net income for the quarter was $-163M. Revenue grew -89.9% year-over-year compared to Q3 2024. Operating income came in at $-173M.

In Q2 2025, Vir Biotechnology, Inc. reported revenue of $1M and earnings per share (EPS) of $-0.80. Net income for the quarter was $-111M. Gross margin was 99.1%. Revenue grew -60.5% year-over-year compared to Q2 2024. Operating income came in at $-118M.

Over the past 8 quarters, Vir Biotechnology, Inc. has demonstrated a growth trajectory, with revenue expanding from $3M to $7M. Investors analyzing VIR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

VIR Dividend Yield and Income Analysis

Vir Biotechnology, Inc. (VIR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

VIR Momentum and Technical Analysis Profile

Vir Biotechnology, Inc. (VIR) has a momentum factor score of 66/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 17/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

VIR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Vir Biotechnology, Inc. (VIR) ranks #293 out of 838 stocks based on the Blank Capital composite score. This places VIR in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing VIR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VIR vs S&P 500 (SPY) comparison to assess how Vir Biotechnology, Inc. stacks up against the broader market across all factor dimensions.

VIR Next Earnings Date

No upcoming earnings date has been announced for Vir Biotechnology, Inc. (VIR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy VIR? — Investment Thesis Summary

The quantitative profile for Vir Biotechnology, Inc. suggests caution. The quality score of 37/100 flags below-average profitability. The value score of 16/100 indicates premium valuation. Price momentum is positive at 66/100, suggesting the trend favors buyers. High volatility (stability score 35/100) increases portfolio risk.

In summary, Vir Biotechnology, Inc. (VIR) earns a Reduce rating with a composite score of 39.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VIR stock.

Related Resources for VIR Investors

Explore more research and tools: VIR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare VIR head-to-head with peers: VIR vs AZN, VIR vs SLGL, VIR vs VMD.